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1. Introduction
Growth factors are proteins with low molecular weight 
that establish intercellular communication at both short 
and long distances. These proteins move in specific cells 
through their specific cell surface receptors and regulate 
cell differentiation, migration, survival, and proliferation 
(1).
It has been reported that there is a rise in more than 
one growth factor in malignant tumors and such factors 
play a role in tumor development, growth, invasion, 
angiogenesis, and metastasis. As one of the growth factors, 
midkine (MK) has been investigated recently in studies 
focusing on elucidating the process of carcinogenesis in 
various cancer types (2–5). The product of the human 
MK gene is a protein that is localized on the 11p11.2 
chromosome; it consists of 143 amino acids, which are 
rich in histidines and cysteine, and weighs approximately 
13 kDa (6–8). MK has been reported to be a retinoic acid-
sensitive gene product and a heparin-binding growth 
factor in embryonic carcinoma cells (6,9). It has been 
argued that MK increases mitotic activity and causes some 
cells to turn malignant (10,11). It is said to be expressed 
at a minimum level in normal tissues but at a high level 
in many malignant and inflammatory diseases (12). 
MK expression has been reported to increase often and 
regularly in human cancer types and that it can serve as a 
tumor marker and a molecular target for cancer treatment 
(13). The serum MK level is said to increase considerably 
in the early stages of many cancer types (14). 
Today, cancer is one of the major factors leading to 
human deaths. Lung, breast, prostate, and colorectal 
cancers constitute nearly half of all cancer deaths and new 
cancer cases. It is stated that there has been a decrease at 
a rate of 0.4% in the incidence of cancer every year from 
2001 to 2010. This decrease in cancer incidence was found 
to occur in males while rates remained fixed in females. 
Background/aim: Midkine (MK), a heparin-binding growth factor, has an important role in cancer progression. The aim of this study 
was to determine MK expression in breast tissue and the preoperative and postoperative serum levels of patients with breast cancer.
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In fact, the incidence of breast cancer in women is said to 
increase (15). With its different histological manifestations, 
biological performance, clinical findings, and responses 
to treatment, breast cancer is a disease with malignancy 
having many pathological subtypes (16,17). Deaths due to 
breast cancer generally occur due to the growth of distant 
metastases that cannot be detected with the existing 
treatments (18). Approximately 69% of women who are 
diagnosed with advanced-stage breast cancer die within 5 
years (19). 
Breast cancer is seen in one of every four women. 
Our aim was to explore the presence of MK expression in 
cancerous breast tissues, which is thought to be a marker 
capable of detecting cancer at an early stage, through 
immunohistochemical and cDNA techniques and its 
serum levels.
2. Materials and methods
Included in the study were 110 individuals who presented 
to the General Surgery Breast Outpatient Clinic of the 
Faculty of Medicine of Pamukkale University between 
August 2013 and August 2014 and who volunteered. Care 
was taken to ensure that the subjects did not have any other 
disease (liver disorders, rheumatoid arthritis, diabetes, 
hypertension, etc.). Our patient group consisted of 61 
subjects who were diagnosed with breast cancer. As study 
material, we used the subjects’ tissue samples that were 
fixed in 10% formaldehyde solution and then embedded 
in paraffin blocks. Serum samples were obtained from 
blood samples that were taken before the patients 
diagnosed with breast cancer were operated on and from 
samples that were taken for routine examinations 15–30 
days after the operation. The control group consisted of 
49 female patients who underwent a breast operation for 
noncancerous reasons and had nontumoral breast tissues, 
and their preoperative serum samples were also obtained. 
The pathology reports of the patients containing data 
on their ages, menopause statuses, biopsy methods, and 
presence of any other disease as well as their information 
from the breast outpatient clinic were reviewed and 
such reports were used to determine the subject groups 
according to their tumor grades and stages. 
2.1. Immunohistochemistry
Each case’s samples with maximum microvessel density and 
minimum hemorrhage and necrosis were selected and were 
fixed in 10% formalin, and sections of 3–5 µm from paraffin-
embedded tissue were placed on adhesive polylysine-
coated slides. Sections were incubated in blocking solution 
to eliminate nonspecific immunoreactivity and then the 
anti-MK monoclonal antibody (mid green (C terminus) 
rabbit monoclonal antibody, Medical Biogen) was reacted 
with it. After removal of excess antibody by washing with 
PBS, the samples marked with horseradish peroxidase 
goat antimouse or antirabbit antibodies were incubated 
for 60 min. DAB substrate reaction can be monitored 
by the system and opposite sections were treated with a 
hematoxylin staining procedure (20,21). Samples were 
considered negative if less than 5% of the cells stained 
for MK. Weak positive was defined as 5%–25% staining, 
positive as 25%–50% staining, and strongly positive as 
more than 50% of cells stained positively in cytoplasm 
(22).
Each section was evaluated by two pathologists without 
patient identification information and clinical diagnosis 
was performed under a conventional light microscope. 
2.2. RNA extraction and cDNA synthesis
Total RNA from formalin-fixed, paraffin-embedded 
(FFPE) sections of 4–5 µm was isolated using the 
RNeasy FFPE kit (QIAGEN, Germany) according to the 
manufacturer’s instructions. Total RNA concentrations 
were measured with a biophotometer (Eppendorf, 
Germany) and 1 µg of RNA was used as a template for 
the synthesis of complementary DNA (cDNA) using the 
QuantiTect Reverse Transcription Kit (QIAGEN). Reverse 
transcription was carried out 42 °C for 15 min followed 
by incubation at 95 °C for 3 min. The cDNAs were stored 
at –20 °C until they were used as a template in real-time 
PCR. 
2.2.1. Real-time quantitative PCR
Quantitation of the MK gene and an internal reference gene 
(β-actin) at mRNA level was done using a fluorescence-
based real-time detection method (LightCycler 2.0, 
Roche, Germany). Final reaction volume for the analysis 
of MK expression at mRNA level was 20 µL: 2 µL of each 
primer (final concentration: 0.5 µM), 2 µL of probe (final 
concentration: 0.2 µM), 4 µL of 5X LightCycler TaqMan 
Master Mix, 5 µL of DNA or cDNA sample, and 5 µL of 
PCR-grade water. The cycling conditions were 95 °C for 10 
min, followed by 45 cycles at 95 °C for 10 s, 60 °C for 20 s, 
and 72 °C for 1 s. All runs included one negative DNA or 
cDNA control consisting of DNase- and RNase-free water. 
MK expression at mRNA level was relatively quantified 
using β-actin in each tumor and the final results were 
obtained with LightCycler software (version 3). 
2.3. Serum MK measurement
Serums were separated by centrifuging the blood samples 
for approximately 30 min after they were taken into 
plain gelled tubes. The serums were then stored at –20 
°C immediately after they were separated until the time 
they would be studied. When the measurements were to 
be carried out, the frozen serums were melted at room 
temperature and 100 µL of these serums were used for 
measurements. After performing the procedure steps as 
instructed by the ELISA kit (Cusabio, China), readings 
were taken at 450 nm to measure MK levels in ng/mL. 
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2.4. Statistical analysis
Statistical analysis was performed with SPSS 17.0 (SPSS 
Inc., Chicago, IL, USA). Continuous variables were 
expressed as mean ± standard deviation and categorical 
variables as numbers and percentages. Continuous 
variables were compared with the independent sample 
t-test or Mann–Whitney U test with one-way ANOVA. P 
< 0.05 was considered statistically significant for all tests. 
3. Results
When the mean age of the 61 subjects in the patient group, 
which was 53.38 ± 13.74 years, was compared to that of 
the control group, which was 44.00 ± 12.89 years, it was 
statistically highly significant (P = 0.000). Two of our 
subjects diagnosed with cancer were males (3.3%).
Positive MK expression was seen in the breast tissues 
of 44 (72.1%) of the 61 cancer patients who took part in 
our study. As for immunohistochemical staining statuses 
of breast tissues, the breast tissue samples of 17 patients 
did not show any staining (Figure 1A); 17 showed weak 
positive (Figure 1B), 11 positive (Figure 2A) and 16 
strongly positive staining (Figure 2B) (Table 1). When the 
MK expression in breast tissues was evaluated with respect 
to immunohistochemical staining status, no significant 
difference was found in terms of tumor diameter, lymph 
node metastasis, stage, nuclear grade, histological grade, 
lymphatic and neural invasion, or age. 
When the MK expression at mRNA level was evaluated 
through real-time relative quantification in 40 samples 
chosen randomly, presence of expression at mRNA level 
was seen in 3 subjects (7.5%). The immunohistochemical 
characteristics of the breast tissues of the patients 
who were found to have mRNA expression were also 
positive. One patient had positive immunohistochemical 
expression (25%–50%) in her breast tissue and the other 
two patients had strongly positive expression (50%). 
  
A B  
 
A B  
Figure 1. MK expression in breast tissues. Breast tissue samples that did not show immunohistochemical staining (A) 40× 
and that showed weak staining (B) 40×.
Figure 2. Samples that had positive (A) 100× and strongly positive (B) 40× immunohistochemical MK expression in breast 
tissues. 
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However, when the MK expression in breast tissues was 
evaluated immunohistochemically, we could not obtain 
any mRNA expression although we had other patients 
who had positive and strongly positive staining. 
The mean serum MK level was 1.77 ± 0.38 ng/mL 
(mean ± SD) in the healthy individuals who took part in our 
study and formed the control group. When the individuals 
who formed the control group were assessed for their 
menopausal status, no difference was seen between the 
serum MK levels of the patients in menopause (1.65 ± 0.22 
ng/mL) and those of the patients in premenopausal period 
(1.84 ± 0.44 ng/mL) (P = 0.978).
When we compared the mean preoperative serum MK 
level of the patient group (3.68 ± 2.13 ng/mL) with the 
mean serum MK level of the control group (1.77 ± 0.38 
ng/mL), we found that the serum MK level of the patient 
group was considerably higher and it was statistically 
highly significant. A comparison of the serum MK level 
of the patient group before the operation (3.68 ± 2.13 ng/
mL) with that after the removal of the tumor (2.47 ± 1.00 
ng/mL) showed that postoperative MK level dropped and 
this was statistically highly significant (P = 0.000) (Figure 
3). There was not any statistical significance when the 
preoperative serum MK levels of the patients who had a 
tumor diameter of 2 cm or less and of the patients who 
had a tumor diameter larger than 2 cm were compared (P 
= 0.924). Again, no statistical significance was found when 
the mean serum MK level of the patients who had lymph 
node metastasis was compared with the mean serum MK 
level of the patients who had no lymph node metastasis 
(Table 2). 
When we grouped our patients by cancer stages, we 
had one patient at stage III and three patients at stage IV. 
Since the number of patients at these two stages was small, 
we considered them to be in the same group and grouped 
them to be at stage III. The serum MK levels of the patients 
who were at stage III before their tumors were removed 
were higher than the serum MK levels of the patients at 
both stage I and stage II and this was statistically significant. 
The postoperative serum MK levels were close to each 
other in all stages and this was not statistically significant. 
As there was only one nuclear grade stage 1 patient, she 
was included in stage 2, and thus nuclear grade stages 2 
and 3 were assessed. When MK levels were analyzed in 
terms of nuclear and histological grades, no statistical 
significance was seen. When we explored the mean MK 
levels of the patients who had a lymphatic invasion and/
or neural invasion, they showed an increase in those who 
had a lymphatic invasion and the increase was higher in 
those who had a neural invasion. The serum MK levels of 
Table 1. Immunohistochemical staining statuses of breast cancer patients with respect to clinical parameters.
Clinical parameters -(0%–5%)  
+
(5%–25%)
++
(25%–50%)
+++
(>50%) Total
Tumor size (cm) ≤2>2
5 (19.2%) 
12 (34.3%) 
9 (19.2%)
8 (34.3%)
4 (15.4%)
7 (20.0%)
8 (30.8%)
8 (22.9%)
26 (100%)
35 (100%)
Lymph node metastasis -+
8 (28.6%)
9 (27.3%)
7 (25%)
10 (30.3%)
5 (17.9%)
6 (18.2%)
8 (28.6%)
8 (24.2%)
28 (100%)
33 (100%)
Stage
I 
II 
III
9 (24.3%)
5 (25%) 
3 (75%)
10 (27%)
6 (30%)
1 (25%)
8 (21.6%)
3 (15%)
0 (0%)
10 (27%)
6 (30%)
0 (0%)
37 (100%)
20 (100%)
4 (100%)
Nuclear grade 2 3
3 (20%)
14 (30.4%)
3 (20%)
14 (30.4%)
5 (33.3%)
6 (13.0%)
4 (26.7%)
12 (26.1%)
15 (100%)
46 (100%)
Histological grade
1 
2 
3
0 (0%)
7 (25.9%)
10 (32.3%)
2 (66.7%)
8 (29.6%)
7 (22.6%)
0 (0%)
7 (25.9%)
4 (12.9%)
1 (33.3%)
5 (18.5%)
10 (32.3%)
3 (100%)
27 (100%)
31 (100%)
Lymphatic and perineural invasion -+
9 (23.7%)
8 (34.8%)
12 (31.6%)
5 (21.7%)
9 (23.7%)
2 (8.7%)
8 (21.1%)
8 (34.8%)
38 (100%)
23 (100%)
Age <50≥50
9 (23.1%)
8 (36.4%)
12 (30.8%)
5 (22.7%)
7 (17.9%)
4 (18.2%)
11 (28.2%)
5 (22.7%)
39 (100%)
22 (100%)
Total 17 17 11 16 61
 
Staining statuses: 0%–5% negative (-), 5%–25% weak positive (+), 25%–50% positive (++), and >50% strongly positive (+++).
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Figure 3. Serum MK levels of control and patients groups.
Table 2. Serum MK levels of breast cancer patients with respect to their clinical parameters.
Clinical parameters (n) *Preop.(ng/mL) P-values
**Postop. 
(ng/mL) P-values
Tumor size (cm) ≤2>2
26
35
3.71 ± 2.16
3.65 ± 2.14
n.s.
2.64 ± 1.09
2.34 ± 0.93
n.s.
Lymph node metastasis -+
28
33
3.69 ± 2.26
3.66 ± 2.06
n.s.
2.53 ± 1.00
2.41 ± 1.02
n.s.
Stage
I 
II 
III
37
20
4
3.71 ± 2.09
3.09 ± 1.49
6.29 ± 3.61
I-III, P = 0.050
I-II, P = 0.520
II-III, P = 0.016
2.57 ± 1.03
2.26 ± 0.96
2.58 ± 1.10
n.s.
Nuclear grade 2 3
15
46
3.86 ± 1.84
3.62 ± 2.24
n.s.
2.37 ± 0.89
2.50 ± 1.05
n.s.
Histological grade
1 
2 
3
3
27
31
2.52 ± 0.39
3.77 ± 1.78
3.71 ± 2.50
n.s.
2.04 ± 0.20
2.60 ± 1.17
2.39 ± 0.88
n.s.
Lymphatic and perineural invasion
–
Lymph +
Neural + 
Lymph+neur+
32
14
6
9
3.37 ± 1.98
3.68 ± 1.85
4.22 ± 2.12
4.40 ± 3.06
n.s.
2.28 ± 0.80
2.86 ± 1.32
3.02 ± 1.15
2.17 ± 0.85
n.s.
Age <50≥50
39
22
3.80 ± 2.31
3.46 ± 1.81
n.s.
2.48 ± 1.05
2.44 ± 0.94
n.s.
 
(Lymph+neur+: lymph and perineural invasion + ). n.s.: not significant (P > 0.05).
*Preop.: preoperative mean serum MK levels ± SD;     **Postop.: postoperative mean serum MK levels ± SD.
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the patients who had both lymphatic and neural invasions 
were the highest. The serum MK levels of the patients who 
did not have any lymphatic or neural invasion were the 
lowest, but when they were compared with those of the 
patients who had lymphatic and neural invasions, this was 
not statistically significant (Table 2). 
Our patients who were diagnosed with breast cancer 
had one or more of the following breast cancer types: 
invasive ductal carcinoma (IDC), ductal carcinoma in situ 
(DCIS), lobular carcinoma in situ (LCIS), and mucinous 
carcinoma (Mca). There were 18 (29.5%) patients who had 
IDC alone and 32 (52.5%) patients who had both the IDC 
and DCIS types. All three types of IDC, DCIS, and LCIS 
were found in 2 (3.3%) patients. IDC and DCIS together 
with Mca were seen in 3 (4.9%) patients. One (1.6%) 
person had Mca, 2 (3.3%) had LCIS, and 2 (3.3%) had 
DCIS types of breast cancer. There was 1 (1.6%) patient 
who had both IDC and Mca types. 
We assessed our patients as the IDC and DCIS groups 
with respect to their breast cancer types. In the IDC group, 
the serum MK levels of the patients who had no lymph 
node metastasis were lower than those of the patients who 
had lymph node metastasis, but this was not statistically 
significant. The mean serum MK level of the DCIS group 
patients was higher than that of the IDC group patients 
with or without lymph node metastasis. While a significant 
drop was seen in the postoperative mean serum MK level 
of the DCIS patients, the drop in the serum MK level of 
IDC patients was less (Table 3).
4. Discussion
When expressed by tumor cells and/or stromal cells, growth 
factors contribute to a large extent to tumor formation 
and development. A large number of studies have shown 
that the level of growth factors in circulation increases in 
cancer patients compared to healthy individuals and such 
growth factors may stimulate focuses of metastasis in an 
endocrinal way (23). MK is a multifunctional growth 
hormone that can induce various effects in the targeted 
cells including nerve cells, neutrophils, macrophages, 
smooth muscle cells, fibroblasts, and tumor cells. It plays a 
role in tumor development, growth, invasion, angiogenesis, 
and metastasis (4,5). For this reason, some researchers 
have focused on investigating the MK expression as 
one of the growth factors and on the relationship of this 
expression with tumor types and sizes and its serum values 
(13,14,20,22,24). 
MK mRNA and protein expressions have been 
frequently seen to rise in many human carcinomas such as 
lung, breast, stomach, colorectal, urinary bladder, prostate, 
glioblastoma, neuroblastoma, and Wilms tumors (25–31). 
It has been reported that MK expression is higher in cancer 
tissues than in normal cervical tissues and 88.1% of cancer 
tissues show reaction to anti-MK antibody (22).
MK expression was seen in 78.6% of osteosarcoma 
tissue samples (32), 54% of samples from patients with 
gastrointestinal stromal tumors (20), 89% of samples 
from patients with thyroid invasive papillary carcinoma 
(33), and 76.4% of gastric cardiac adenocarcinoma 
samples (34). It has also been reported that excessive MK 
is secreted in cancerous breast tissues (35) and positive 
MK expression is seen in 86% of IDC breast cancer cases 
(21). In our study, we found MK expression in 44 (72.1%) 
of the breast tissue samples of 61 breast cancer patients 
through the immunohistochemical method. We observed 
immunohistochemical MK expression in 42 breast tissues 
(73.6%) from 58 IDC cases. The immunohistochemical 
findings of our study are similar to those of previous 
studies. 
It has been stated that in cervical cancer cases MK 
protein expression is associated with cancer stages, 
histology, and tumor diameter (22), and there is no 
relation between tumor diameter and MK expression in 
gastrointestinal stromal tumors but it has an important 
association with proliferative index (20). Qin et al. pointed 
out that high MK expression in breast cancer is associated 
with lymph node metastasis and TNM stages but not with 
age, menopausal status, or tumor diameter (21). We found 
Table 3. Pre- and postoperative mean serum MK levels and immunohistochemical staining statuses of breast cancer patients with 
respect to their cancer types.
Breast cancer types n *Preop. (ng/mL) P-values
**Postop.
(ng/mL) P-values IHC - IHC +
IDC lymph node metastasis - 25 3.50 ± 1.67 2.61 ± 1.04 7 (28%) 18 (72%)
IDC lymph node metastasis + 33 3.66 ± 2.06 P = 0.611 2.41 ± 1.02 P = 0.617 9 (27.3%) 24 (72.7%)
DCIS lymph node metastasis - 3 5.26 ± 5.63 1.93 ± 0.08 1 (33.3%) 2 (66.7%)
*Preop.: preoperative mean serum MK levels ± SD.
**Postop.: postoperative mean serum MK levels ± SD.
225
ÇETİN SORKUN et al. / Turk J Med Sci
in our study that when MK expression was assessed in an 
immunohistochemical way in the cancerous breast tissues 
with respect to the patients’ clinical parameters, it did not 
show any statistical significance. 
We were able to find expression of MK at mRNA level 
in only 3 (7.5%) of the randomly selected 40 subjects in 
our study. Moon et al. found the mRNA expression of MK 
at a rate of 88.1% in patients with cervical cancer (22). We 
think that the reason for finding a low mRNA expression in 
our study is that the sample tissues studied were obtained 
from paraffin blocks. Obtaining the mRNA expression 
level from fresh tissues of the patients with breast cancer 
could have allowed us to reach more accurate results. 
It has been reported that since MK is a secretion 
protein, it can also be found in the peripheral blood of 
patients who have tumors that release a lot of MK. The MK 
expression in esophageal carcinoma tissue has a significant 
relationship with its increase in serum level (5,36,37). 
It has been stated that the plasma MK level is higher 
in patients with breast cancer when compared to controls 
and the MK level is significantly higher in metastatic 
cancer patients than the levels in primary invasive cancer 
and DCIS. However, it has been reported that there is 
no significant difference with respect to tumor diameter, 
nodal status, clinical stage, vascular invasion, hormone 
receptor status, and HER2 status (24). It was reported 
in the study of Ikematsu et al. that the serum MK level 
of cancer patients was higher than that of the control 
group. However, it was also reported that the increase 
in the serum MK level in various cancer types was not 
associated with tumor diameter or stage. They reported 
that the serum MK level increased even at an early stage 
(stage I) in patients with stomach cancer and lung cancer. 
It was observed that after surgically removing the tumor 
tissues of 5 patients with liver cancer, the serum MK 
level dropped significantly in 4 patients (14). When we 
compared the serum MK levels of healthy individuals 
and our patients diagnosed with cancer in our study, we 
found that it was statistically highly significantly different. 
When we measured the postoperative serum MK levels of 
our patients, we saw that they decreased considerably and 
there was statistical significance. When we examined our 
patients with respect to their stages, we found that the mean 
serum MK level of the stage III group was significantly 
higher than those of the stage I group and stage II group. 
The mean serum MK levels of the patients in stages I and 
II were significantly higher than the mean serum MK level 
of healthy individuals. Our study is similar in this respect 
to the study of Krzystek-Korpacka et al., who stated that 
the MK level went up depending on the cancer stages in 
patients with colorectal cancer and it was significantly 
high even at an early stage. It was also reported in the same 
study that the serum MK level was higher in patients with 
lymph node metastasis (38). Although we also found in 
our study that the serum MK level was higher in patients 
with lymph node metastasis, we did not find this to be 
statistically significant. The serum MK level also did not 
show any significance with respect to tumor diameter, age, 
histological and nuclear grade, or lymphatic and neural 
invasions. The serum MK levels of the IDC patients who 
had lymph node metastasis were high in our study, but this 
was not statistically significant. In this respect, our study 
differs from that of Tanabe et al., who stated that the serum 
MK level was significantly correlated with lymph node 
metastasis in endometrial carcinoma (39). Nevertheless, 
the fact that the postoperative decrease in the serum MK 
levels was low in our IDC patients suggests that metastasis 
may have occurred in these patients. 
In conclusion, it has been seen in our study and other 
studies that there is an increase in MK expression in the 
presence of tumors. The fact that this expression increases 
at the serum level even at early stages and that there is a 
decrease in the serum MK level after the tumor has been 
removed shows that MK can be used as a cancer marker. 
However, we found in our study that the postoperative 
serum MK level dropped only a little in some of the 
patients. There is a need for further studies that will 
monitor patients who had serum MK levels that did not 
drop and investigate whether or not such serum MK 
levels that remained high were associated with metastasis. 
Such studies to be carried out will provide important 
contributions to the use of MK as a cancer marker.                    
 
Acknowledgments
We appreciate the Scientific and Technological Research 
Council of Turkey for financial support of this study 
(Project No. 113S056), Nurse Döne Dinger from the 
General Surgery Breast Outpatient Clinic of the Pamukkale 
University Hospitals, Technician Murat Dalkıran, and 
Tuncay Dural from the Clinical Laboratories of the 
Pamukkale University Hospitals.
References
1. Hunter T. Signaling—2000 and beyond. Cell 2000; 100: 113–
127.
2. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An 
angiogenic role for the neurokines midkine and pleiotrophin in 
tumorigenesis. Cancer Res 1997; 57: 1814–1819.
226
ÇETİN SORKUN et al. / Turk J Med Sci
3. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, 
Noda M, Muramatsu T, Kadomatsu K. Haptotactic migration 
induced by midkine. Involvement of protein-tyrosine 
phosphatase zeta. Mitogen-activated protein kinase, and 
phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 15868–
15875.
4. Muramatsu T. Midkine and pleiotrophin: two related proteins 
involved in development, survival, inflammation and 
tumorigenesis. J Biochem 2002; 132: 359–371. 
5. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in 
neural development and cancer. Cancer Lett 2004; 204: 127–
143.
6. Matsubara S, Tomomura M, Kadomatsu K, Muramatsu T. 
Structure of a retinoic acid-responsive gene, MK, which is 
transiently activated during the differentiation of embryonal 
carcinoma cells and the mid-gestation period of mouse 
embryogenesis. J Biol Chem 1990; 265: 9441–9443.
7. Kaname T, Kuwano A, Murano I, Uehara K, Muramatsu T, Kajii 
T. Midkine gene (MDK), a gene for prenatal differentiation and 
neuroregulation, maps to band 11p11.2 by fluorescence in situ 
hybridization. Genomics 1993; 17: 514–515.
8. Murasugi A, Tohma-Aiba Y. Production of native recombinant 
human midkine in the yeast, Pichia pastoris. Protein Expr 
Purif 2003; 27: 244–252.
9. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning 
and sequencing of a new gene intensely expressed in early 
differentiation stages of embryonal carcinoma cells and in mid-
gestation period of mouse embryogenesis. Biochem Biophys 
Res Commun 1988; 151: 1312–1318.
10. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, 
Muramatsu T. Midkine induces the transformation of NIH3T3 
cells. Br J Cancer 1997; 75: 354–359. 
11. Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, 
Burrow CR. Midkine induces tumor cell proliferation and 
bind to a high affinity signaling receptor associated with JAK 
tyrosine kinase. J Biol Chem 1998; 273: 3654–3660.
12. Muramatsu T. Midkine, a heparin-binding cytokine with 
multiple roles in development, repair and diseases. Proc Jpn 
Acad Ser B Phys Biol Sci 2010; 86: 410–425.
13. Sakamoto K, Kadomatsu K. Midkine in the pathology of 
cancer, neural disease, and inflammation. Pathol Int 2012; 62: 
445–455.
14. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano 
H, Okamoto K, Oda M, Sakuma S, Aikou T et al. Serum 
midkine levels are increased in patients with various types of 
carcinomas. Br J Cancer 2000; 83: 701–706.
15. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, 
Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA et al. 
Annual Report to the Nation on the status of cancer, 1975-2010, 
featuring prevalence of comorbidity and impact on survival 
among persons with lung, colorectal, breast, or prostate cancer. 
Cancer 2014; 120: 1290–1314.
16. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees 
CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. Molecular 
portraits of human breast tumours. Nature 2000; 406: 747–752.
17. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen 
H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. Gene 
expression patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. P Natl Acad Sci USA 
2001; 98: 10869–10874.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 
100: 57–70.
19. Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. 
Assessing non-cancer-related health status of US cancer 
patients: other-cause survival and comorbidity prevalence. Am 
J Epidemiol 2013; 178: 339–349.
20. Kaifi JT, Fiegel HC, Rafnsdottir SL, Aridome K, Schurr PG, 
Reichelt U, Wachowiak R, Kleinhans H, Yekebas EF, Mann O et 
al. Midkine as a prognostic marker for gastrointestinal stromal 
tumors. J Cancer Res Clin Oncol 2007; 133: 431–435.
21. Qin LL, Huang HL, Ping JL, Xu W, Li J, Dai LC. Expression 
of midkine and endoglin in breast carcinomas with different 
immunohistochemical profiles. APMIS 2010; 119: 103–110.
22. Moon HS, Park W, Sung SH, Choi EA, Chung HW, Woo BH. 
Immunohistochemical and quantitative competitive PCR 
analyses of midkine and pleiotrophin expression in cervical 
cancer. Gynecol Oncol 2003; 88: 289–297.
23. Kuroi K, Toi M. Circulating angiogenesis regulators in cancer 
patients. Int J Biol Markers 2001; 16: 5–26.
24. Ibusuki M, Fujimori H, Yamamoto Y, Ota K, Ueda M, Shinriki 
S, Taketomi M, Sakuma S, Shinohara M, Iwase H et al. Midkine 
in plasma as a novel breast cancer marker. Cancer Sci 2009; 
100: 1735–1739.
25. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, 
Hamanoue M, Takao S, Shimazu H, Ohi Y, Muramatsu T. A 
new family of heparin-binding growth/differentiation factors: 
increased midkine expression in Wilms’ tumour and other 
human carcinomas. Cancer Res 1993; 53: 1281–1285.
26. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner 
PG. Midkine and pleiotrophin expression in normal and 
malignant breast tissue. Cancer 1994; 74: 1584–1590. 
27. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou 
T, Muramatsu T. Increased midkine gene expression in human 
gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655–661.
28. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, 
Cnaan A, Brodeur GM. Differential expression of pleiotrophin 
and midkine in advanced neuroblastomas. Cancer Res 1995; 
55: 1792–1797.
29. O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The 
angiogenic factor midkine is expressed in bladder cancer, and 
overexpression correlates with a poor outcome in patients with 
invasive cancers. Cancer Res 1996; 56: 2515–2518.
30. Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita 
Y, Muramatsu T, Kurino T. Increased expression of midkine 
during the progression of human astrocytomas. Neurosci Lett 
1997; 233: 29–32.
227
ÇETİN SORKUN et al. / Turk J Med Sci
31. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura 
H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical 
analysis of midkine expression in human prostate carcinoma. 
Oncology 1999; 57: 253–257.
32. Sueyoshi T, Jono H, Shinriki S, Ota K, Ota T, Tasaki M, 
Atsuyama E, Yakushiji T, Ueda M, Obayashi K et al. Therapeutic 
approaches targeting midkine suppress tumor growth and lung 
metastasis in osteosarcoma. Cancer Lett 2012; 316; 23–30.
33. Kato M, Maeta H, Kato S, Shinozawa T, Terada T. 
Immunohistochemical and in situ hybridization analyses 
of midkine expression in thyroid papillary carcinoma. Mod 
Pathol 2000; 13: 1060–1065.
34. Hu XF, Yao J, Gao SG, Yang YT, Peng XQ, Feng XS. Midkine and 
syndecan1 levels correlate with the progression of malignant 
gastric cardiac adenocarcinoma. Mol Med Rep 2014; 10: 1409–
1415.
35. Miyashiro I, Kaname T, Shin E, Wakasugi E, Monden T, 
Takatsuka Y, Kikkawa N, Muramatsu T, Monden M, Akiyama 
T. Midkine expression in human breast cancers: expression of 
truncated form. Breast Cancer Res Treat 1997; 43: 1–6.
36. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu 
K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T. Increased 
serum midkine concentration as a possible tumor marker in 
patients with superficial esophageal cancer. Oncol Rep 2003; 
10: 411–414.
37. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, 
Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai 
T. Preoperative serum midkine concentration is a prognostic 
marker for esophageal squamous cell carcinoma. Cancer Sci 
2003; 94: 628–632.
38. Krzystek-Korpacka M, Diakowska D, Neubauer K, Gamian 
A. Circulating midkine in malignant and non-malignant 
colorectal diseases. Cytokine 2013; 64: 158–164.
39. Tanabe K, Matsumoto M, Ikematsu S, Nagase S, Hatakeyama 
A, Takano T, Niikura H, Ito K, Kadomatsu K, Hayashi S et al. 
Midkine and its clinical significance in endometrial carcinoma. 
Cancer Sci 2008; 99: 1125–1130.
